Arena, Vivus’ Obesity Drugs See Continual Uptake, Persistence Key Among Primary Care Docs

by Elizabeth Krutoholow

 

Arena’s Belviq and Vivus’ Qsymia have been readily adopted by weight loss experts, according to Dr. Ken Fujioka, director, Nutrition and Metabolic Research and of the Center for Weight Management at Scripps Clinic.

 

Persistence of use, particularly among primary care doctors will be critical for the companies to maintain this trajectory and generate revenue. It is also yet to be seen if patients will accept higher out-of-pocket costs to remain on Qsymia or Belviq after promotional periods end.

 

Read more >>>

 

Bloomberg BRIEF Newsletters